• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/30/25 5:23:18 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email
    8-K
    false000072838700007283872025-05-302025-05-30

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 30, 2025

     

     

    Perspective Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-33407

    41-1458152

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    c/o Perspective Therapeutics, Inc.

    2401 Elliott Avenue

    Suite 320

     

    Seattle, Washington

     

    98121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (206) 676-0900

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    CATX

     

    NYSE American LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 8.01 Other Events.

    On May 30, 2025, Perspective Therapeutics, Inc. issued a press release and posted to its website a presentation announcing certain interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors (NETs) that are being presented at the 2025 American Society of Clinical Oncology Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. A copy of the press release is filed herewith as Exhibit 99.1, and a copy of the presentation is filed herewith as Exhibit 99.2, and each is incorporated herein by reference.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit No.

     

    Description

    99.1

     

    Press Release dated May 30, 2025.

    99.2

     

    Investor Presentation.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    PERSPECTIVE THERAPEUTICS, INC.

     

     

     

     

    Date:

    May 30, 2025

    By:

    /s/ Johan (Thijs) Spoor

     

     

     

    Johan (Thijs) Spoor
    Chief Executive Officer

     


    Get the next $CATX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    9/25/2024$21.00Buy
    Truist
    7/25/2024$24.00Buy
    BofA Securities
    5/9/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00

      3/13/25 7:26:51 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Scotiabank initiated coverage on Perspective Therapeutics with a new price target

      Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00

      3/7/25 8:03:16 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously

      11/25/24 7:39:30 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 6:44:41 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:04:49 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:03:59 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 6:44:41 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:04:49 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:03:59 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    SEC Filings

    See more
    • Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

      7/3/25 8:02:07 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

      6/23/25 6:32:13 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

      6/3/25 8:05:34 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

      Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

      6/24/25 12:52:00 PM ET
      $AUTL
      $CATX
      $INDP
      $ONCY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

      SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana. Lead authorAbstract TitlePresentation DetailsStephen Graves[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-α-NET-T101 trialAbstract Number: 251949Session Type: Poster & OralPoster Session Date: June 21, 2025Oral session: MTA07 Oncology: Clinic

      6/21/25 8:00:54 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

      [212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical dataOn track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their

      6/21/25 8:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    See more
    • Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

      Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

      6/24/25 12:52:00 PM ET
      $AUTL
      $CATX
      $INDP
      $ONCY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

      6/18/25 11:19:00 AM ET
      $CATX
      $CGON
      $GALT
      $ONCY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

      SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). "In less than 18 months, Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform,

      1/6/25 8:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Financials

    Live finance-specific insights

    See more
    • Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

       Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatmentFour of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject

      5/30/25 5:21:00 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

        Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

      1/24/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

      SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will

      1/22/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Perspective Therapeutics Inc.

      SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/14/24 6:14:40 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

      SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/14/24 4:05:13 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

      SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/7/24 9:24:55 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care